Andrea Lobo,  —

A 38-year-old woman in Portugal developed atypical hemolytic uremic syndrome (aHUS) despite showing no typical markers of the disease after she experienced gastrointestinal inflammation, according to a case report. “This case highlights the diagnostic and management challenges in aHUS when traditional disease markers are absent and emphasizes the importance…

Hip surgery triggered atypical hemolytic uremic syndrome (aHUS) in a 49-year-old woman, who was successfully treated with plasma exchange, which is a blood-cleaning procedure, and kidney replacement therapy, according to a case study in India. A prompt diagnosis and multidisciplinary collaboration, as well as early and aggressive treatment of…

This year’s aHUS Awareness Day, Sept. 24, will highlight mental health issues important to people with atypical hemolytic uremic syndrome (aHUS) and their families. The annual event is being organized by the aHUS Alliance, an international umbrella organization that comprises patient groups and aHUS advocates to support patients,…

A U.S. woman with atypical hemolytic uremic syndrome (aHUS) has been in disease remission for 13 years while receiving treatment with C5 complement inhibitors after undergoing a kidney transplant, a new report details. According to the researchers, this is the longest reported case in the literature of an aHUS…

A woman developed atypical hemolytic uremic syndrome (aHUS) after receiving the first dose of a COVID-19 vaccine, according to a case study from Brazil. The researchers said the “connection of symptoms post-COVID-19 vaccination to aHUS … emphasizes the need for ongoing monitoring and research into vaccine-related complications.” The case…

A woman in her 60s developed atypical hemolytic uremic syndrome (aHUS) as a result of severe babesiosis, a tick-borne parasitic infection, according to a recent U.S. case report. Babesiosis is caused by a parasite that infects red blood cells. The disease is transmitted from the bite of an infected tick…

Atypical hemolytic uremic syndrome (aHUS) starting during adolescence is associated with more permanent and severe kidney dysfunction when compared with infantile-onset disease, a study from Turkey reported. “In the long term, adolescents may have significant permanent loss of [kidney] functions and higher [end-stage kidney disease] rates,” the researchers wrote.

Soliris (eculizumab) can effectively induce and maintain remission of atypical hemolytic uremic syndrome (aHUS) in children with autoantibodies that target complement factor H (FH). That’s according to a study that found the therapy reduced anti-FH antibodies no matter the type of immunosuppressive treatments used with it. They also…

Use of the drug Soliris (eculizumab) effectively treated atypical hemolytic uremic syndrome (aHUS) in a pregnant woman in her 30s who developed the rare disease after having placental abruption, which occurs when the placenta separates from the inner wall of the uterus before birth. Her case was described…

Soliris (eculizumab) was used to effectively treat atypical hemolytic uremic syndrome (aHUS) in a young woman with systemic lupus erythematosus (SLE), another autoimmune condition, a case report shows. The therapy was safely discontinued without causing an aHUS relapse, while immunosuppressant treatments for SLE were maintained. This “case highlights…